NIBL Ace to invest in HMDL

KATHMANDU: Mr. Shivanth Bahadur Pande, Chief Executive Officer of NIBL Ace, and Mr. Abhishek Dugar, Vice Chairperson and CEO of H. Medical & Diagnostic Private Limited (HMDL), a division of Dugar Healthcare, signed a definitive investment agreement on Nov 27, 2022, according to NIBL Ace Capital Limited (“NIBL Ace”).

HMDL has grown to become one of the leading companies in the medical tech and diagnostic sectors, developing, producing, and marketing futuristic diagnostic products such as medical equipment, reagents, pharmaceutical drugs, and other products in collaboration with Tata Medical and Diagnostics, a wholly owned subsidiary of TATA Group, India’s largest salt to software conglomerate. HMDL, which was founded in 2021 in the midst of the COVID-19 pandemic, quickly established itself by importing low-cost PCR kits manufactured by Tata Medical and Diagnostics.

So much so that it has captured a significant market share in Nepal by developing a highly recognizable brand portfolio and strong sales of COVID PCR kits and reagents. HMDL also introduced a Tata-made mobile diagnostic van that can reach the most remote areas in Nepal’s mountainous regions to perform diagnostic tests.

With the admirable goal of providing affordable healthcare throughout Nepal, the company intends to establish and operate fully fledged manufacturing units to produce diagnostic and reagents products in Nepal, in addition to establishing high tech futuristic diagnostic centers throughout the country and launching various products and services in collaboration with TATA medical and diagnostics, India.

Their entire business strategy would revolve around incorporating futuristic and emerging technologies into healthcare. They will also collaborate with other diagnostic labs and hospitals to provide integrated and cost-effective healthcare solutions to the public.